Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cancer predisposition due to variation(s) in the CHEK2 gene. Pathogenic germline variation in CHEK2 confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including breast cancer and prostate cancer.
No clinical trials have been registered for CHEK2-related cancer predisposition.
4 publications have been identified in PubMed for CHEK2-related cancer predisposition. Kisho has analyzed 3 by research type. Research spans Epidemiology / Natural History (67%) and Review / Meta-Analysis (33%).
Kim SY (2025). [PMID: 41396600](https://pubmed.ncbi.nlm.nih.gov/41396600/). *JAMA network open*. [Epidemiology / Natural History]
Kalia SS (2024). [PMID: 39259185](https://pubmed.ncbi.nlm.nih.gov/39259185/). *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. [Review / Meta-Analysis]
Kim SY (2024). [PMID: 39371170](https://pubmed.ncbi.nlm.nih.gov/39371170/). *medRxiv : the preprint server for health sciences*. [Epidemiology / Natural History]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
Common questions about CHEK2-related cancer predisposition